Proceedings from a CME symposium held at the 2019 ASCO Annual
Meeting. Featuring perspectives from Dr Daniel P Petrylak, Prof
Thomas Powles and Dr Jonathan E Rosenberg.
Introduction (00:00)
Program overview: Dr Love
Current Role of Anti-PD-1/PD-L1 Antibodies in the
Management of Advanced Urothelial Bladder Carcinoma (UBC)
(1:13)
Case (Dr Petrylak): A woman in her mid-60s with metastatic UBC
who experienced rapid disease progression on first-line
gemcitabine/cisplatin (1:49)
Case (Dr Rosenberg): A man in his late 70s with metastatic UBC
who was ineligible for cisplatin-based chemotherapy and achieved a
complete response to first-line pembrolizumab (11:02)
Newly Approved and Investigational Novel Agents and
Strategies Beyond Immune Checkpoint Inhibition(16:44)
Case (Dr Petrylak): A woman in her mid-60s with metastatic UBC
who enrolled on a clinical trial of enfortumab vedotin and achieved
a complete remission (24:42)
Case (Prof Powles): A man in his mid-60s with metastatic UBC
whose disease progressed rapidly on gemcitabine/cisplatin and
pembrolizumab who began treatment with enfortumab vedotin
(28:09)
Future Applications of Anti-PD-1/PD-L1 Antibodies Alone
or in Combination with Other Systemic Approaches(41:26)
Case (Dr Rosenberg): A woman in her early 60s with widespread
metastatic UBC who experienced disease progression on single-agent
nivolumab and was switched to nivolumab/ipilimumab (45:05)
Case (Prof Powles): A man in his mid-60s with transitional cell
carcinoma who received neoadjuvant atezolizumab on a clinical trial
(54:33)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.